기업 프로필 · Healthcare

Thermo Fisher Scientific Inc

TMO · 미국
거래소
미국
국가 / 지역
USA
상장일
1978년 1월 13일
직원 수
125,000
현재가
$464.61
실시간 · 2026년 6월 18일
베일리 성장 점수
47/100
다소 약함
내재가치 · 3단계 구간 현재가 $464.61 실시간 · 적정 내재가치 구간 내

종합 밸류에이션 구간 · 보수적 $340–$385 / 적정 $440–$495 / 낙관적 $545–$615. $464.61 기준, 적정 내재가치 구간 내.

보고서 발행 시 $448.28(2026년 5월 25일)

이 종목에 대한 리포트가 아직 해당 언어로 없습니다.

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

시가총액US$1715.74억
매출 (TTM)US$451.97억
EBITDAUS$112.96억
순이익률15.15%
ROE13.52%
PER (TTM)25.37
선행 PER18.52
PEG1.52
EPSUS$18.20
배당수익률0.37%
52주 범위US$389.08 – US$642.71
애널리스트 목표주가US$599.19
애널리스트 평가4.4 / 5

데이터 제공: EODHD, 보고 통화 기준 표시. 참고용일 뿐 투자 자문이 아닙니다.

연혁

준비 중이 섹션은 작성 중입니다. 곧 다시 확인해 주세요.

업계 내 위치

준비 중이 섹션은 작성 중입니다. 곧 다시 확인해 주세요.